

STATEMENT BY APPLICANT

JUL 16 2007

(use ~~2~~ many sheets as necessary)

Sheet

1

of

2

COMPLETE IF KNOWN

Application Number

10/578,955

Filing Date

May 10, 2006

First Named Inventor

Evans, Robert, K.

Group Art Unit

1648

Examiner Name _____

~~not assigned~~ Chen, Stacy

Attorney Docket Number

21575P

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	B01	PCT	WO 98/02522	abstract only	Transgene S.A.	01/22/1998
	B02	PCT	WO 99/41416		Schering Corporation	08/19/1999
	B03	PCT	WO 00/61726	abstract only	Aventis Pharma SA	10/19/2000
	B04	PCT	WO 01/66137		Merck & Co., Inc.	09/13/2001
	B05	PCT	WO 01/02607		Merck & Co., Inc.	01/11/2001
	B06	PCT	WO 02/22080		Merck & Co., Inc.	03/21/2002

Examiner
Signature

ALL REFERENCES CONSIDERED EXCEPT WHERE	INFO THROUGH. /SBC/
	Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/578,955
Filing Date	May 10, 2006
First Named Inventor	Evans, Robert, K.
Group Art Unit	1648
Examiner Name	to be assigned
Attorney Docket Number	21575P

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	C01	Brody et al. "Adenovirus-Mediated In Vivo Gene Transfer", Annals New York Academy of Sciences, Vol. 716, pp 90-101 (1994)
	C02	Croyle et al. "Factors that Influence Stability of Recombinant Adenoviral Preparations for Human Gene Therapy", Pharmaceutical Development and Technology, 3(3), pp 373-383 (1998)
	C03	Gray et al. "Compatibility of Various Preservatives with Live Virus Vaccines", International Symposium on Preservatives in Biological Products, Develop. Biol. Standard., Vol. 24, pp 123-129 (1974)
	C04	Hierholzer et al. "Adenoviruses from Patients with AIDS: A Plethora of Serotypes and A Description of Five New Serotypes of Subgenus D (Types 43-47)", The Journal of Infectious Diseases, Vol. 158, No. 4, pp 804-813 (October 1988)
	C05	Horne et al. "The Icosahedral Form of an Adenovirus", J. Mol. Biol. pp 84-86 (1959)
	C06	Horwitz et al. "Adenoviridae and Their Replication", in Fields Virology, Second Edition, pp 1679-1721, (1990)
	C07	Jong et al. "Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains that Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively", Journal of Clinical Microbiology, Vol. 37, No. 12, pp 3940-3945, (1999)
	C08	Kebbe "Chlorobutanol", Handbook of Pharmaceutical Excipients, 3rd Ed., pp 126-128, (2000)
	C09	Kowalski et al. "The Survival of Adenovirus in Multidose Bottles of Topical Fluorescein", American Journal of Ophthalmology, Volume 126, Issue 6, pp 835-836, (December 1998)
	C10	Nair et al. "The Kinetics of Degradation of Chlorobutanol", J. Am. Pharmaceutical Assoc., Volume XLVII, pp 390-395, (1959)
	C11	Nyberg-Hoffman et al. "Instability of Adenoviral Vectors during Transport and its Implication for Clinical Studies", Nature Medicine Inc., Volume 5, Number 8, pp 955-956, (August 1999)
	C12	Romanowski et al. "The Survival of Herpes Simplex Virus in Multidose Office Ophthalmic Solutions", Volume 128, Issue 2, pp 239-240, (August 1999)
	C13	Schurr et al. "Two New Candidate Adenovirus Serotypes", Intervirology, Vol. 36, pp 79-83, (1993)
	C14	Straus et al. "Adenovirus Infections in Humans", in The Adenoviruses, Plenum Press, pp 451-496, (1984)
	C15	Wadell et al. "Genetic Variability of Adenoviruses", Annals New York Academy of Sciences, Vol. 354, pp 16-42, (1980)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

Examiner Signature	/Stacy B. Chen/	Date Considered	12/17/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007